NEWS & EVENTS

Latest news and upcoming events

26 May 2021

Ysios Capital closes its third fund at €216 million ($260 million)

Upcoming events

  • Biospain 2021
    29 September – 1 October 2021,
    Pamplona, Spain

  • Biotech Europe Forum 2021
    7 October – 8 October 2021,
    Digital

  • Venture Capital Forum 2021
    13 October – 14 October 2021,
    Digital

13 Jul 2021

LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies

LAVA’s first-in-class gamma-delta bsTCE to be evaluated as a treatment for chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.
08 Jul 2021

Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve

Patient’s own tissue naturally turn device into living heart valves and may reduce need for re-interventions
07 Jul 2021

Adcendo Appoints Michael Pehl as Chief Executive Officer

Experienced Industry Leader with successful Oncology, Immunotherapy & ADC Development Track Record
06 Jul 2021

AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board

Mr. Altmeyer will provide important guidance as the Company expands its global clinical development program.
05 Jul 2021

Ysios Capital’s portfolio company CVRx Inc. prices IPO on NASDAQ

This is a major achievement for Ysios as CVRx is its fifth portfolio company to be listed on NASDAQ, and the second within just three months.
01 Jul 2021

AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial

REVIVAL study is evaluating ilofotase alfa, the Company’s proprietary recombinant human alkaline phosphatase, for the treatment of sepsis-associated acute kidney injury (SA-AKI).
18 Jun 2021

Aura Biosciences Assembles New Bladder Cancer Focused Scientific Advisory Board

The new SAB will be comprised of seven members and will work closely with Aura’s senior management.
16 Jun 2021

AM-Pharma Appoints Martijn Negen as VP Commercial Strategy

Martijn Negen has over 20 years of experience in pharmaceutical, biotech and diagnostic companies.
15 Jun 2021

VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board

VarmX today announces the appointment of Dr. Gerard Short, MBBS, as Chief Medical Officer (CMO).
14 Jun 2021

CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting

These data confirmed the ability of the CorWave pump to provide chronic circulatory support with exceptional hemocompatibility.

Newsletter

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.